Valuations as Mediators Between Science and the Market: How Economic Assumptions Shape Pharmaceutical Trial Designs

References

• Abraham, J. and Davis, C. (2007) Deficits, expectations and paradigms in British and American drug safety assessments: Prising open the black box of regulatory science, Science, Technology, & Human Values, 32(4), pp. 399–431. doi: 10.1177/0162243907301002
   Web of Science ®Google Scholar
• Bijker, W. E. and Pinch, T. J. (1987) The social construction of facts and artifacts: Or how the sociology of science and the sociology of technology might benefit each other, in: W. E. Bijker, T. P. Hughes and T. J. Pinch (Eds) The Social Construction of Technological Systems: New Directions in the Sociology and History of Technology, pp. 17–50 (Cambridge: MIT Press).
   Google Scholar
• Callon, M. (1986) Some elements of a sociology of translation: Domestication of the scallops and the fishermen of St-Brieuc Bay, in: J. Law (Ed.) Power, Action and Belief: A New Sociology of Knowledge?, pp. 196–233 (London: Routledge & Kegan Paul).
   Google Scholar
• Callon, M. (1991) Techno-economic networks and irreversibility, in: J. Law (Ed.) A Sociology of Monsters: Essays on Power, Technology and Domination, pp. 132–164 (London: Routledge).
   Google Scholar
• Callon, M. (1998a) Introduction: The embeddedness of economic markets in economics, in: M. Callon (Ed.) The Laws of the Markets, pp. 1–57 (Oxford: Blackwell).
   Google Scholar
• Callon, M. (ed.) (1998b) The Laws of the Markets (Oxford: Blackwell).
   Google Scholar
• Callon, M., Millo, Y., and Muniesa, F. (eds) (2007) Market Devices (Oxford: Blackwell).
   Google Scholar
• Carpenter, D. (2010) Reputation and Power: Organisational Image and Pharmaceutical Regulation at the FDA (Princeton, NJ: Princeton University Press).
   Google Scholar
• Chevret, S. (2012) Bayesian adaptive clinical trials: A dream for statisticians only?, Statistics in Medicine, 31(11–12), pp. 1002–1013. doi: 10.1002/sim.4363
   PubMed Web of Science ®Google Scholar
• Chuang-Stein, C. and Beltangady, M. (2010) FDA draft guidance on adaptive design clinical trials: Pfizer’s perspective, Journal of Biopharmaceutical Statistics, 20(6), pp. 1143–1149. doi: 10.1080/10543406.2010.514456
   PubMed Web of Science ®Google Scholar
• Dussauge, I., Helgesson, C.-F., Lee, F., and Woolgar, S. (2015) On the omnipresence, diversity, and elusiveness of values in the life sciences and medicine, in: I. Dussauge, C.-F. Helgesson and F. Lee (Eds) Value Practices in the Life Sciences and Medicine, pp. 1–28 (Oxford: Oxford University Press).
   Google Scholar
• Eichler, H.-G., Pignatti, F., Flamion, B., Leufkens, H., and Breckenridge, A. (2008) Balancing early market access to new drugs with the need for benefit/risk data: A mounting dilemma, Nature Reviews Drug Discovery, 7(10), pp. 818–826. doi: 10.1038/nrd2664
   PubMed Web of Science ®Google Scholar
• Elsäßer, A., Regnstrom, J., Vetter, T., Koenig, F., Hemmings, R. J., Greco, M., Papaluca-Amati, M., and Posch, M. (2014) Adaptive clinical trial designs for European marketing authorization: A survey of scientific advice letters from the European medicines agency, Trials, 15(1), pp. 383–392. doi: 10.1186/1745-6215-15-383
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. (2007) Reflection Paper on Methodological Issues in Confirmatory Clinical Trials Planned with an Adaptive Design (London: EMEA).
   Google Scholar
• European Medicines Agency and EFPIA. (2010) EMA/EFPIA 2nd workshop adaptive design in confirmatory trials. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/events/2009/11/event_detail_000007.jsp&mid=WC0b01ac058004d5c3 (accessed 7 January 2015)
   Google Scholar
• Fisher, L. D. (1999) Advances in clinical trials in the twentieth century, Annual Review of Public Health, 20, pp. 109–124. doi: 10.1146/annurev.publhealth.20.1.109
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. (2006) Critical Path Opportunities Report (Washington, DC: FDA).
   Google Scholar
• Food and Drug Administration. (2010) Guidance for Industry Adaptive Design Clinical Trials for Drugs and Biologics, Draft Feb 2010 (Washington, DC: FDA).
   Google Scholar
• Fourcade, M. (2011) Cents and sensibility; economic valuation and the nature of ‘nature’, American Journal of Sociology, 116(6), pp. 1721–1777. doi: 10.1086/659640
   Web of Science ®Google Scholar
• Godin, B. (2006) The linear model of innovation: The historical construction of an analytical framework, Science, Technology & Human Values, 31(6), pp. 639–667. doi: 10.1177/0162243906291865
   Web of Science ®Google Scholar
• Helgesson, C.-F. (2016) Editorial note: Folded valuations?, Valuation Studies, 4(2), pp. 93–102. doi: 10.3384/VS.2001-5992.164293
   Google Scholar
• Helgesson, C.-F. and Muniesa, F. (2013) For what it’s worth: An introduction to valuation studies, Valuation Studies, 1(1), pp. 1–10. doi: 10.3384/vs.2001-5992.13111
   Google Scholar
• Helgesson, C.-F., Lee, F., and Lindén, L. (2016) Valuations of experimental designs in proteomic biomarker experiments and traditional randomised controlled trials, Journal of Cultural Economy, 9(2), pp. 157–172. doi: 10.1080/17530350.2015.1108215
   Web of Science ®Google Scholar
• Kjellberg, H. and Helgesson, C.-F. (2007) On the nature of markets and their practices, Marketing Theory, 7(2), pp. 137–162. doi: 10.1177/1470593107076862
   Google Scholar
• Krams, M. and Dragalin, V. (2014) Considerations and optimization of adaptive trial design in clinical development programs, in: W. He, J. Pinheiro and O. M. Kuznetsova (Eds) Practical Considerations for Adaptive Trial Design and Implementation, pp. 69–90 (New York: Springer).
   Google Scholar
• Lamont, M. (2012) Toward a comparative sociology of valuation and evaluation, Annual Review of Sociology, 38(1), pp. 201–221. doi: 10.1146/annurev-soc-070308-120022
   Web of Science ®Google Scholar
• Latour, B. (1987) Science in Action: How to Follow Scientists and Engineers Through Society (Cambridge: Harvard University Press).
   Google Scholar
• Lee, F. (2015) Purity and interest: On interest work and epistemic value, in: I. Dussauge, C.-F. Helgesson and F. Lee (Eds) Value Practices in the Life Sciences and Medicine, pp. 207–223 (Oxford: Oxford University Press).
   Google Scholar
• MacKenzie, D. (2006) An Engine, Not a Camera: How Financial Models Shape Markets (Cambridge: MIT Press).
   Google Scholar
• MacKenzie, D. (2009) Material Markets: How Economic Agents Are Constructed (Oxford: Oxford University Press).
   Google Scholar
• MacKenzie, D. and Millo, Y. (2003) Constructing a market, performing theory: The historical sociology of a financial derivatives exchange, American Journal of Sociology, 109(1), pp. 107–145. doi: 10.1086/374404
   Web of Science ®Google Scholar
• MacKenzie, D., Muniesa, F., and Siu, L. (Eds). (2007) Do Economists Make Markets? On the Performativity of Economics (Princeton, NJ: Princeton University Press).
   Google Scholar
• Marchenko, O., Fedorov, V., Lee, J. J., Nolan, C., and Pinheiro, J. (2014) Adaptive clinical trials: Overview of early-phase designs and challenges, Therapeutic Innovation & Regulatory Science, 48(1), pp. 20–30. doi: 10.1177/2168479013513889
   PubMed Web of Science ®Google Scholar
• Marks, H. M. (1997) The Progress of Experiment: Science and Therapeutic Reform in the United States, 1900–1990 (Cambridge: Cambridge University Press).
   Google Scholar
• Miller, P., and O’Leary, T. (2007) Mediating instruments and making markets: Capital budgeting, science and the economy, Accounting, Organizations and Society, 32(7–8), pp. 701–734. doi: 10.1016/j.aos.2007.02.003
   Web of Science ®Google Scholar
• Montgomery, C. M. (2017) From standardization to adaptation: Clinical trials and the moral economy of anticipation, Science as Culture, 26(2), pp. 232–254. doi: 10.1080/09505431.2016.1255721
   Web of Science ®Google Scholar
• Moreira, T. (2012) The Transformation of Contemporary Health Care: The Market, the Laboratory, and the Forum (New York: Routledge).
   Google Scholar
• Muniesa, F. (2012) A flank movement in the understanding of valuation, in: L. Adkins and C. Lury (Eds) Measure and Value, pp. 24–38 (Oxford: Wiley-Blackwell).
   Google Scholar
• Pickering, A. (1995) The Mangle of Practice: Time, Agency, and Science (Chicago, IL: University of Chicago Press).
   Google Scholar
• Rabeharisoa, V. and Doganova, L. (2016) Making rareness count: Testing and pricing orphan drugs. i3 Working Paper Series. Available at http://www.i-3.fr/en/workingpaper/making-rareness-count-testing-and-pricing-orphan-drugs/ (accessed 18 October 2016).
   Google Scholar
• Roscoe, P. (2015) A moral economy of transplantation: Competing regimes of value in the allocation of transplant organs, in: I. Dussauge, C.-F. Helgesson and F. Lee (Eds) Value Practices in the Life Sciences and Medicine, pp. 99–118 (Oxford: Oxford University Press).
   Google Scholar
• Shea, M. B., Roberts, S. A., Walrath, J. C., Allen, J. D., and Sigal, E. V. (2013) Use of multiple endpoints and approval paths depicts a decade of FDA oncology drug approvals, Clinical Cancer Research, 19(14), pp. 3722–3731. doi: 10.1158/1078-0432.CCR-13-0316
   PubMed Web of Science ®Google Scholar
• Sjögren, E. (2006) Reasonable drugs: Making decisions with ambiguous knowledge, Published PhD diss, Stockholm School of Economics, 2006.
   Google Scholar
• Sjögren, E., and Helgesson, C.-F. (2007) The Q(u)ALYfying hand: Health economics and medicine in the shaping of Swedish markets for subsidised pharmaceuticals, in: M. Callon, Y. Millo and F. Muniesa (Eds) Market Devices, pp. 215–240 (Oxford: Blackwell).
   Google Scholar
• Tufts CSDD. (2013) R&D senior leadership brief: The adoption and impact of adaptive trial designs. Tufts Center for the Study of Drug Development. Available at http://csdd.tufts.edu/files/tuftscsdd_adaptive_trials.pdf (accessed 8 January 2015).
   Google Scholar
• Will, C. and Moreira, T. (2010) Introduction: Medical proofs social experiments: Clinical trials in shifting contexts, in: C. Will and T. Moreira (Eds) Medical Proofs, Social Experiments: Clinical Trials in Shifting Contexts, pp. 1–13 (Aldershot: Ashgate).
   Google Scholar
• Zuiderent-Jerak, T. and van Egmond, S. (2015) Ineffable cultures or material devices: What valuation studies can learn from the disappearance of ensured solidarity in a health care market, Valuation Studies, 3(1), pp. 45–73. doi: 10.3384/VS.2001-559.153145
   Google Scholar